News
Biostem Technologies
BSEM · OTC
$1.64+$0.10 (+6.49%)TodayMarket closed ·
Prev close $1.54
Latest news
- Press releaseGlobe Newswire
BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer
- Press releaseGlobe Newswire
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
- Press releaseGlobe Newswire
BioStem Technologies Highlights Alignment with FDA's Openness to Bayesian Statistical Approaches in Clinical Research
- Press releasePRNewswire
BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies
- Press releaseGlobe Newswire
BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings' Surgical and Wound Care Business
- Press releaseGlobe Newswire
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
- Press releaseGlobe Newswire
BioStem Technologies Products Placed on "12-Month Status Quo Period" List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
- Press releaseGlobe Newswire
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant
- Press releaseGlobe Newswire
BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results
- Press releaseGlobe Newswire
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
- Press releaseGlobe Newswire
BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million
- Press releaseGlobe Newswire
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
- Press releaseGlobe Newswire
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.